Affimed N.V. (AFMD) Stock Forecast for 2024, 2025, 2026. Sell or Buy Prediction
All stock predictions
All currency forecasts
All cryptocurrency predictions

This Month Predictions for AFMD stock
Affimed N.V. Analysis
AFMD Stock News


Popular stocks:
Suncor Energy
Carnival
NVIDIA
TAL Education
Boeing
GameStop
Alibaba
Tesla
Tilray
Uber

TOP Stocks:
Microsoft
Apple
Tesla
Alibaba
Amazon
American Airlines
NVIDIA
Adobe

Shares of other companies:
Veeva Systems
Eargo
EVgo
The Charles Schwab
Sea Limited
Lennar
Marathon Oil
Team
Axon Enterprise
Sorrento Therapeutics


Financial News

Popular Stocks Analysis

Investor's Journal
When to Switch Payroll Solutions and How to Make a Smooth Transition

December 9, 2024 When to Switch Payroll Solutions and How to Make a Smooth Transition

Payroll solutions are important for every business, as without them, you cannot make the right choices and calculations in your payment system. However,…
Latest Finance Management Regulations in Australia

November 24, 2024 Latest Finance Management Regulations in Australia

Navigating the maze of Finance Regulations can feel like trying to solve a puzzle without all the pieces. Just when you think you’ve…
Finance Management Education Resources

November 24, 2024 Finance Management Education Resources

Trying to manage money without guidance can feel like wrestling an octopus—in the dark. You’re sifting through credit card offers, debating investment options,…
Best Backtesting Software For Traders

November 18, 2024 Best Backtesting Software For Traders

Trading isn’t merely about numbers flickering on a screen; it’s a dynamic journey fraught with challenges and discoveries. I remember countless nights poring…
Best Forex Trading Tools

November 18, 2024 Best Forex Trading Tools

Selecting the ideal Forex Trading Tools can feel like trying to solve a jigsaw puzzle without the picture—overwhelming, right? So many options, each…
  1. Home
    2. »
  2. Stock forecasts
    3. »
  3. AFMD

Affimed N.V. (AFMD) Stock Forecast for 2024, 2025, 2026. Sell or Buy?

Updated: December 11, 2024 (03:04)

Sector: Healthcare

The share price of Affimed N.V. (AFMD) now

Latest session on the 10th of December for
Affimed N.V. is negative
Trading Volume: 423774
Open: 2.4 /  High: 2.45 /  Low: 2.192
What analysts predict: $28.25
52-week High/Low: $8.95 / $2.25
50-Day Moving Average: $3.216 — resistance level today
200-Day Moving Average: $4.645 — resistance level today

News Impact Analyzer

Full report
This Week
 Bullish Impact: 5 News: 1 (1/0/0)
Previous Week
 Na Impact: Na News: Na
Two Weeks Ago
 Na Impact: Na News: Na
Three Weeks Ago
 Bearish Impact: 5 News: 2

Analyzing the Most Important AFMD news

Affimed's Lymphoma Breakthrough: Promising Phase 2 Results

Dec 09, 2024
Trend: Bullish
Influence: 8
Affimed's announcement of an 86% overall response rate and 55% complete response for its lymphoma treatment is highly promising. These results enhance the drug's market potential, generating investor optimism. This positive clinical outcome is likely to boost confidence in Affimed's growth prospects, potentially elevating stock price significantly in the short to medium term.

Affimed Reports Steep Revenue Decline: Q3 EPS Dips to -€0.94

Nov 14, 2024
Trend: Bearish
Influence: 8
The significant year-over-year revenue decline of 91.8% and a negative EPS of -€0.94 suggest major financial challenges for Affimed. Despite reduction in net cash used for operations, the information indicates high-risk concerns, thus reflecting a strong bearish outlook. This is likely to exert downward pressure on AFMD stock in the near future.

Affimed Prepares for Potentially Challenging Q3 Earnings Release

Nov 13, 2024
Trend: Bearish
Influence: 7
The anticipated significant EPS drop and negative revenue growth signal a bearish outlook for Affimed. Despite the company's past success in beating revenue estimates, the downward revisions and zero EPS estimate surpasses raise concerns. Such factors may hinder investor confidence, likely influencing a decline in stock price post-earnings announcement.

Historical and forecast chart of Affimed N.V. stock

The chart below shows the historical price of Affimed N.V. stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Affimed N.V. stock price can be found in the table below.

Long-term forecasts by years.

Comprehensive Analysis of Affimed N.V. (AFMD) Stock Market Performance


Our multifaceted analysis of Affimed N.V.'s stock market is grounded in the company's key news stories, insights from reputable analysts, as well as mathematical and technical evaluations. Taking into account assessments from each of these aspects in real-time helps us address the most crucial questions for investors in the most objective way possible:

  • When should I take profit in Affimed N.V. stock?
  • When should I record a loss on Affimed N.V. stock?
  • What are analysts' forecasts for Affimed N.V. stock?
  • What is the future of Affimed N.V. stock?

We forecast Affimed N.V. stock performance using neural networks based on historical data on Affimed N.V. stocks.

Affimed N.V. News influencing stock rates

As of now, Panda has combed through 3 news items directly related to AFMD from the last 30 days. Out of these, 1 clearly showcase a bullish trend, while 2 display bearish tendencies, and 0 events are neutral.

The strength of the bearish trend is dominating bullish sentiments by 1.78 times, indicating that the current news landscape is negatively impacting the company's stock prices in the foreseeable future.

The news analyzed fell within the period from Nov 13, 2024, to Dec 09, 2024.

βeta
Nov 04, 2024

Affimed Plans $20M Mixed Securities Issuance

Trend: Bearish
Influence: 5
The filing for a $20M mixed securities shelf can signal a need for additional capital, which investors might interpret as a cash flow issue. This can lead to short-term bearish sentiment. However, the impact is moderate as it's a standard move for companies to raise funds for future growth, keeping long-term outlook neutral.

Affimed N.V., a clinical-stage biopharmaceutical company, is engaged in the discovery and development of immunotherapy treatments for cancer in the United States, Europe and Germany. The lead product candidate is AFM13, which has completed a Phase II clinical trial for CD30-positive T-cell lymphoma and Hodgkin’s lymphoma (HL) and is in Phase II clinical trials for peripheral T-cell lymphoma and transformed fungal mycosis.

Trending Themes in the Healthcare Sector

Affimed N.V. daily forecast for a month

Date Target Pes. Opt. Vol., %
Dec 13 2.28 2.24 2.31 3.01
Dec 14 2.27 2.22 2.29 3.23
Dec 15 2.22 2.17 2.28 5.03
Dec 16 2.21 2.15 2.24 3.87
Dec 17 2.23 2.20 2.29 3.81
Dec 18 2.26 2.21 2.32 5.11
Dec 19 2.29 2.22 2.31 4.00
Dec 20 2.26 2.21 2.29 3.38
Dec 21 2.18 2.11 2.22 5.11
Dec 22 2.18 2.14 2.22 3.83
Dec 23 2.18 2.13 2.25 5.91
Dec 24 2.26 2.19 2.32 5.98
Dec 25 2.33 2.26 2.38 5.15
Dec 26 2.34 2.32 2.39 3.11
Dec 27 2.38 2.34 2.45 4.43
Dec 28 2.40 2.35 2.45 4.34
Dec 29 2.42 2.37 2.48 4.57
Dec 30 2.39 2.35 2.45 4.18
Dec 31 2.31 2.28 2.33 2.02
Jan 01 2.25 2.20 2.30 4.54
Jan 02 2.22 2.16 2.27 5.00
Jan 03 2.23 2.18 2.29 5.07
Jan 04 2.30 2.27 2.34 3.12
Jan 05 2.30 2.26 2.34 3.42
Jan 06 2.30 2.27 2.32 2.23
Jan 07 2.30 2.25 2.35 4.12
Jan 08 2.29 2.22 2.35 5.91
Jan 09 2.23 2.17 2.26 3.98
Jan 10 2.24 2.20 2.28 3.42
Jan 11 2.22 2.18 2.25 3.35

Affimed N.V. Daily Price Targets


Affimed N.V. Stock Forecast 12-13-2024.

Forecast target price for 12-13-2024: $2.28.
Negative dynamics for Affimed N.V. shares will prevail with possible volatility of 2.924%.
Pessimistic target level: 2.24
Optimistic target level: 2.31

Affimed N.V. Stock Forecast 12-14-2024.

Forecast target price for 12-14-2024: $2.27.
Negative dynamics for Affimed N.V. shares will prevail with possible volatility of 3.131%.
Pessimistic target level: 2.22
Optimistic target level: 2.29

Affimed N.V. Stock Forecast 12-15-2024.

Forecast target price for 12-15-2024: $2.22.
Negative dynamics for Affimed N.V. shares will prevail with possible volatility of 4.786%.
Pessimistic target level: 2.17
Optimistic target level: 2.28

Affimed N.V. Stock Forecast 12-16-2024.

Forecast target price for 12-16-2024: $2.21.
Negative dynamics for Affimed N.V. shares will prevail with possible volatility of 3.724%.
Pessimistic target level: 2.15
Optimistic target level: 2.24

Affimed N.V. Stock Forecast 12-17-2024.

Forecast target price for 12-17-2024: $2.23.
Positive dynamics for Affimed N.V. shares will prevail with possible volatility of 3.667%.
Pessimistic target level: 2.20
Optimistic target level: 2.29

Affimed N.V. Stock Forecast 12-18-2024.

Forecast target price for 12-18-2024: $2.26.
Positive dynamics for Affimed N.V. shares will prevail with possible volatility of 4.866%.
Pessimistic target level: 2.21
Optimistic target level: 2.32

AFMD (AFMD) Monthly Stock Prediction for 2025

Month Target Pes. Opt. Vol., %
Jan. 2.51 2.42 2.57 5.85
Feb. 2.70 2.60 2.77 6.20
Mar. 2.73 2.60 2.87 9.59
Apr. 2.65 2.43 2.73 10.86
May. 2.39 2.31 2.58 10.15
Jun. 2.67 2.50 2.87 12.96
Jul. 2.55 2.41 2.74 11.87
Aug. 2.44 2.28 2.66 14.28
Sep. 2.37 2.26 2.57 11.96
Oct. 2.41 2.20 2.54 13.47
Nov. 2.20 2.11 2.33 9.19
Dec. 2.17 2.04 2.34 12.91
Full forecast for 2025

Affimed N.V. forecast for this year


Affimed N.V. Stock Prediction for Jan 2025

An uptrend is forecast for this month with an optimal target price of $2.50615. Pessimistic: $2.42. Optimistic: $2.57


Affimed N.V. Stock Prediction for Feb 2025

An uptrend is forecast for this month with an optimal target price of $2.70463. Pessimistic: $2.60. Optimistic: $2.77


Affimed N.V. Stock Prediction for Mar 2025

An uptrend is forecast for this month with an optimal target price of $2.73384. Pessimistic: $2.60. Optimistic: $2.87


Affimed N.V. Stock Prediction for Apr 2025

An downtrend is forecast for this month with an optimal target price of $2.65183. Pessimistic: $2.43. Optimistic: $2.73


Affimed N.V. Stock Prediction for May 2025

An downtrend is forecast for this month with an optimal target price of $2.39407. Pessimistic: $2.31. Optimistic: $2.58


Affimed N.V. Stock Prediction for Jun 2025

An uptrend is forecast for this month with an optimal target price of $2.67274. Pessimistic: $2.50. Optimistic: $2.87


Affimed N.V. Stock Prediction for Jul 2025

An downtrend is forecast for this month with an optimal target price of $2.55407. Pessimistic: $2.41. Optimistic: $2.74


Affimed N.V. Stock Prediction for Aug 2025

An downtrend is forecast for this month with an optimal target price of $2.43761. Pessimistic: $2.28. Optimistic: $2.66


Affimed N.V. Stock Prediction for Sep 2025

An downtrend is forecast for this month with an optimal target price of $2.37033. Pessimistic: $2.26. Optimistic: $2.57


Affimed N.V. Stock Prediction for Oct 2025

An uptrend is forecast for this month with an optimal target price of $2.41299. Pessimistic: $2.20. Optimistic: $2.54


Affimed N.V. Stock Prediction for Nov 2025

An downtrend is forecast for this month with an optimal target price of $2.19872. Pessimistic: $2.11. Optimistic: $2.33


Affimed N.V. Stock Prediction for Dec 2025

An downtrend is forecast for this month with an optimal target price of $2.1697. Pessimistic: $2.04. Optimistic: $2.34



Affimed N.V. (AFMD) Monthly Stock Prediction for 2026

Month Target Pes. Opt. Vol., %
Jan 2.29 2.14 2.48 13.63
Feb 2.15 2.00 2.36 15.44
Mar 2.16 1.98 2.32 14.82
Apr 2.34 2.25 2.41 6.41
May 2.46 2.36 2.57 7.82
Jun 2.52 2.43 2.71 10.30
Jul 2.60 2.41 2.68 10.00
Aug 2.48 2.33 2.59 10.02
Sep 2.32 2.14 2.51 14.79
Oct 2.22 2.10 2.40 12.57
Nov 2.28 2.17 2.46 11.56
Dec 2.15 1.97 2.21 10.53
Full forecast for 2026

Affimed N.V. (AFMD) Monthly Stock Prediction for 2027

Month Target Pes. Opt. Vol., %
Jan 2.33 2.19 2.41 9.16
Feb 2.52 2.39 2.69 10.94
Mar 2.41 2.30 2.47 6.91
Apr 2.22 2.04 2.30 11.45
May 1.97 1.79 2.05 12.55
Jun 2.02 1.89 2.19 13.67
Jul 2.00 1.82 2.09 12.75
Aug 2.23 2.13 2.39 11.07
Sep 2.32 2.18 2.50 12.51
Oct 2.36 2.15 2.54 15.27
Nov 2.31 2.11 2.45 13.78
Dec 2.19 2.09 2.37 12.08
Full forecast for 2027

Affimed N.V. information and performance

Affimed N.V. Address

IM NEUENHEIMER FELD 582, 69120, HEIDELBERG, DE

Market Capitalization: 38 194 100 $

Market capitalization of the Affimed N.V. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of AFMD shares in the company outstanding by the market price of one share.

EBITDA: -71 172 000 $

EBITDA of Affimed N.V. is earnings before interest, income tax and depreciation of assets.

PE Ratio: None

P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit

PEG Ratio: N/A

Price/earnings to growth

DPS: None

Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.

DY: None

Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.

EPS: -4.82

EPS shows how much of the net profit is accounted for by the common share.

Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: -0.9
Trailing PE: -

Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.

Forward PE: -

Forward P/E uses projections of future earnings instead of final numbers.

EV To Revenue: 27.4

Enterprise Value (EV) /Revenue

EV To EBITDA: 1.133

The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).

Shares Outstanding: 16392300

Number of issued ordinary shares

Shares Float: N/A

Number of freely tradable shares

Shares Short Prior Month: N/A

Shares Short Prior Month - the number of shares in short positions in the last month.

Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A


Related stocks from Healthcare sector

Exelixis, Inc. (EXEL)
Codex DNA, Inc. (DNAY)
Bavarian Nordic A/S (BVNRY)
Zynerba Pharmaceuticals, Inc. (ZYNE)
Quidel Corp. (QDEL)
Alpine Immune Sciences, Inc. (ALPN)
Immix Biopharma, Inc. (IMMX)
Bausch + Lomb Corporation (BLCO)
Aerie Pharmaceuticals, Inc. (AERI)
Biofrontera Inc. (BFRI)


Disclaimer:

All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.